Morgan Stanley’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Morgan Stanley’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,178	Closed	-$21K	–	6761
2017 Q2	$21K	Hold	3,178	–	–	﹤0.01%	6083
2017 Q1	$12K	Hold	3,178	–	–	﹤0.01%	6204
2016 Q4	$12K	Hold	3,178	–	–	﹤0.01%	6124
2016 Q3	$14K	Sell	3,178 -760	-19%	-$3.6K	﹤0.01%	6035
2016 Q2	$18K	Hold	3,938	–	–	﹤0.01%	5895
2016 Q1	$13K	Hold	3,938	–	–	﹤0.01%	6064
2015 Q4	$14K	Sell	3,938 -758	-16%	-$2.99K	﹤0.01%	6160
2015 Q3	$17K	Hold	4,696	–	–	﹤0.01%	6107
2015 Q2	$24K	Buy	4,696 +19	+0.4%	+$132	﹤0.01%	6096
2015 Q1	$37K	Buy	+4,677	New	+$44.3K	﹤0.01%	5896

Morgan Stanley's NVET Position: Q3 2017 in Review

Morgan Stanley sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 3,178 shares — an estimated $21K sold.

Morgan Stanley first reported a position in NVET in Q1 2015 and held it in 10 quarters. The position peaked at $37K in Q1 2015. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

Morgan Stanley reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Morgan Stanley sold 3,178 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $21K.
Morgan Stanley first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 10 quarters.
Morgan Stanley's Nexvet Biopharma plc Ordinary Shares position peaked at $37K in Q1 2015.
0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on Morgan Stanley's 13F filing for Q3 2017, filed 14 Nov 2017.